DOCSLIB.ORG

Acronym Buster

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Acronym Buster Acronym buster This A–Z is designed to help you translate the array of acronyms used in the pharmaceutical industry. ABHI Association of the British Healthcare Industries ACD Appraisal Consultation Document ADTC Area Drug and Therapeutics Committee (Scotland) AE Adverse Event ADR Adverse Drug Reaction AESGP Association of the European Self Medication Industry AGNSS Advisory Group for National Specialised Services AHSC Academic Health Science Centre ANSN Academic Health Science Network AL Adaptive Licensing AMRC Association of the Medical Research Charities AMS Academy of Medical Sciences APG American Pharmaceutical Group APPG All Party Parliamentary Group/All Party Pharmacy Group AQF Annual Quality Framework (health – Wales) AQP Any Qualified Provider WACG All Wales Cancer Drugs Group (supports the AWMSG) AWMSG All Wales Medicines Strategy Group (HTA body for Wales) AWPAG All Wales Prescribing Advisory Group (subgroup of AWMSG) BAEPD British Association of European Pharmaceutical Distributors BAPW British Association of Pharmaceutical Wholesalers BBSRC Biotechnology and Biological Sciences Research Council BGMA British Generic Manufacturers Association BHBIA British Healthcare Business Intelligence Association BIA BioIndustry Association BIG Bioindustrial Innovation and Growth Team (BIS subgroup) BIS Department for Business, Innovation & Skills BMA British Medical Association BNF British National Formulary BNFC British National Formulary for Children BIVDA British In Vitro Diagnostics Association BPG British Pharma Group CAMHS Child and Adolescent Mental Health Services CBI The Confederation of British Industry CCG Cancer Campaigning Group/Clinical Commissioning Group CD Controlled Drugs CHC Community Health Council (Wales) CHM Commission on Human Medicines CHMP Committee for Medicinal Products for Human Use CLA Copyright Licensing Agency CMO Chief Medical Officer CMU Commercial Medicines Unit COF Commissioning Outcomes Framework - NICE COMP Committee for Orphan Medicinal Products CoP Code of Practice (see PMCPA) CPA Chief Pharmaceutical Advisor (Wales) CPO Chief Pharmaceutical Officer (Scotland) CPRD Clinical Practice Research Datalink CQC Care Quality Commission (regulates adult social care services) CQUIN Commissioning for Quality and Innovation CRG Clinical Reference Group CRN Clinical Research Network CRUK Cancer Research UK CSA Chief Scientific Adviser (to the Prime Minister) CSO Commissioning Support Organisation CSR Clinical Study Report CSS Commissioning Support Service CSU Commissioning Support Unit CTA Clinical Trial Authorisation CTD Clinical Trials Directive CTD Common Technical Document (for regulatory submissions) CTR Clinical Trials Regulation DEFRA Department for Environment Food & Rural Affairs DH/DoH Department of Health DHSS Department of Health and Social Services (Wales only) DHSSPS Department of Health, Social Services and Public Safety DSU Decision Support Unit, NICE DSUR Developmental Safety Update Report DTC Direct-to-Consumer DTCA Direct-to-Consumer Advertising D&TC Drug and Therapeutics Committee DTP Direct to Pharmacy/Direct to Public EA Environment Agency EAMS Early Access to Medicines Scheme ECMC Experimental Cancer Medicine Centre Network EFPIA European Federation of Pharmaceutical Industries and Associations EGA European Generic Medicines Association EHR Electronic Health Record EMA European Medicines Agency EMC Electronic Medicines Compendium EMG European Medicines Group EMIG Ethical Medicines Industry Group EMR Electronic Medical Record EPR Electronic Patient Record EPSRC Engineering and Physical Sciences Research Council ERG Evidence Review Groups ESRC Economic and Social Research Council EuropaBio European Association for Bioindustries FAD Final Appraisal Determination FDA Food & Drug Administration (The US licensing authority) FH Foundation Hospital FIH First in Human (regarding clinical studies) FIM First in Man (regarding clinical studies) FMD Falsified Medicines Directive FOI Freedom of Information FPM Faculty of Pharmaceutical Medicine GAVI Global Alliance for Vaccines and Immunisation GCP Good Clinical Practice GDP Good Distribution Practice GLP Good Laboratory Practice GMP Good Manufacturing Practice GVP Good Vigilance (pharmacovigilance) Practice GDG Guideline Development Group GIRP European Association of the Pharmaceutical Full-Line Wholesalers GMC General Medical Council GMS General Medical Services GPC General Practitioners Committee (part of the BMA) GPhC General Pharmaceutical Council HCP Healthcare Professional HEAT targets Health Improvement, Efficiency, Access and Treatment HES Hospital Episode Statistics HFEA Human Fertilisation and Embryology Authority HiS Healthcare Improvement Scotland HPA Health Protection Agency HRA Health Research Authority HRG Healthcare Resource Group HRSS Health Research Support Service HSC Health and Social Care (Northern Ireland) HSCB Health and Social Care Board (Northern Ireland) HSCIC Health and Social Care Information Centre HSE Health Survey for England/Health and Safety Executive HTA Health Technology Assessment HTA Human Tissue Authority IAPO International Association of Patients’ Organisations ICD-10 International Classification of Diseases ICER Incremental Cost-Effectiveness Ratio ICH International Conference on Harmonisation IFPMA International Federation of Pharmaceutical Manufacturers & Associations IP Intellectual Property IVF In Vitro Fertilisation JCVI Joint Committee on Vaccination and Immunisation JPG Japanese Pharmaceutical Group JPMA Japan Pharmaceutical Manufacturers Association JV Joint Venture LCGs Local Commissioning Groups (Northern Ireland) LCRN Local Clinical Research Network LES Local Enhanced Service (part of Quality & Outcomes Framework) LEPs Local Enterprise Partnerships LHB Local Health Board (Wales) LNDG London New Drugs Group LCNDG London Cancer New Drugs Group LPC Local Pharmaceutical Committee LSIDB Life Sciences Innovation Delivery Board LSIO Life Science Investment Organisation LSUK Life Sciences UK LTCAS Long Term Conditions Alliance Scotland M&TC Medicines and Therapeutics Committee (Wales) MA Marketing Authorisation MAA Marketing Authorisation Application MAG Medicines Access Group MAPPs Medicines Adaptive Pathways to Patients MDT Multi-Disciplinary Team MHRA Medicines and Healthcare products Regulatory Agency MISG Ministerial Industry Strategy Group MMF Medicines Management Forum (N. Ireland) MMIT Medicines Management Information Team (N. Ireland) MMPB Medicines Management Programme Board (Wales) MMR Measles, Mumps and Rubella combined vaccine MMTSG Ministerial Medical Technology Strategy Group MPIG Medicines, Pharmacy and Industry Group MRC Medical Research Council NAB National Advisory Board (Wales) NAO National Audit Office NAPC National Association of Primary Care NC3Rs National Centre for the Reduction, Refinement and Replacement of Animals in Research NCAS National Clinical Assessment Service NCASP National Clinical Audit Support Programme NCDG New Cardiovascular Drugs Group (Wales) NCRI National Cancer Research Institute NDA National Diabetes Audit NDA New Drug Application NDC New Drugs Committee/National Drug Code NDG National Delivery Group (Wales) NES NHS Education for Scotland NHS National Health Service NHSBT NHS Blood and Transplant NHSC National Horizon Scanning Centre NHSCB NHS Commissioning Board NHSE NHS England NHSFT NHS Foundation Trust NHS IC NHS Information Centre NHS LA NHS Litigation Authority NHS QIS NHS Quality Improvement Scotland (Scotland) NHS Scotland National Health Service in Scotland NICaN Northern Ireland Cancer Network NICE National Institute for Health and Care Excellence NIHR National Institute for Health Research NIHR CRN National Institute for Health Research Clinical Research Network NIII National Institute for Innovation and Improvement NLIAH National Leadership and Innovation Agency for Healthcare (Wales) NISCHR National Institute for Social Care and Health Research (Wales) NMG New Medicines Group NOCRI National Office for Clinical Research Infrastructure NPA National Pharmacy Association NPC National Prescribing Centre NPSA National Patient Safety Agency NRES National Research Ethics Service NRS NHS Research Scotland NRS Permissions CC NHS Research Scotland Permissions Coordinating Centre NSCG National Specialised Commissioning Group NSF National Service Framework NTA National Treatment Agency OECD Organisation for Economic Co-operation and Development OFT Office of Fair Trading OHE Office of Health Economics OLS Office for Life Sciences ODIG Orphan Diseases Industry Group ONS Office for National Statistics OSCHR Office for the Strategic Coordination of Health Research OTC Over-the-counter (medicines) PACT Prescription Analysis and Cost Tabulation PAGB Proprietary Association of Great Britain PALS Patient Advice and Liaison Service PAPIG Patient and Public Involvement Group PAS Patient Access Scheme PASAG Patient Access Scheme Assessment Group (Scotland) PASLU Patient Access Schemes Liaison Unit WPAS Wales Patient Access Scheme PBC Practice-Based Commissioning PbR Payment by Results PCA Prescription Cost Analysis PCC Patient and Client Council (Northern Ireland) PCP Primary Care Partnerships (Northern Ireland) PCT Primary Care Trust PFA Priorities For Action (Northern Ireland) PHA Public Health Agency (Northern Ireland) PHE Public Health England PIE Pharmaceuticals in the Environment PhRMA Pharmaceutical Research and Manufacturers of America PIL Patient Information Leaflet PISB Pharmaceutical Industry Sector Board PMCPA Prescription Medicines Code of Practice
Load more

Recommended publications
  • A Synopsis of the Joint Environment and Human Health Programme in the UK Michael N Moore*1 and Pamela D Kempton2
    Environmental Health BioMed Central Introduction Open Access A synopsis of the Joint Environment and Human Health Programme in the UK Michael N Moore*1 and Pamela D Kempton2 Address: 1Plymouth Marine Laboratory, Prospect Place, the Hoe, Plymouth, PL1 3DH, UK and 2Natural Environment Research Council, Polaris House, North Star Avenue, Swindon, SN2 1EU, UK Email: Michael N Moore* - [email protected]; Pamela D Kempton - [email protected] * Corresponding author from Joint Environment and Human Health Programme: Annual Science Day Conference and Workshop Birmingham, UK. 24-25 February 2009 Published: 21 December 2009 Environmental Health 2009, 8(Suppl 1):S1 doi:10.1186/1476-069X-8-S1-S1 <supplement>Sciences Research <title> Council <p>Proceedings (BBSRC), Engineering of the Joint and Environment Physical Sciences and Human Research Health Council Programme: (EPSRC) Annual and Health Science Protection Day Conference Agency (HPAand Work).</note>shop</p> </sponsor> </title> <note>Proceedings</note> <editor>Michael N Moore <url>http://www.biomedcentral.com/content/pdf/1476-069X-8-s1-info.pdf</url>and Pamela D Kempton</editor> <sponsor> <note>Publication of this supplement </sup wasplement> made possible with support from the Natural Environment Research Council (NERC), Environment Agency (EA), Department of the Environment &amp; Rural Affairs (Defra), Ministry of Defence (MOD), Medical Research Council (MRC), The Wellcome Trust, Economic &amp; Social Research Council (ESRC), Biotechnology and Biological This article is available from: http://www.ehjournal.net/content/8/S1/S1 © 2009 Moore and Kempton; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • The Impact on Health of Emissions to Air from Municipal Waste Incinerators
    The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency RCE-13 The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency Documents of the Health Protection Agency Radiation, Chemical and Environmental Hazards February 2010 © Health Protection Agency 2010 Contents The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency 1 Summary 1 Introduction 3 Particles 4 Carcinogens 8 Dioxins 9 Epidemiological studies: municipal waste incinerators and cancer 11 Conclusions 11 References 12 Glossary 14 The Impact on Health of Emissions to Air from Municipal Waste Incinerators Advice from the Health Protection Agency Prepared by R L Maynard, H Walton, F Pollitt and R Fielder Summary The Health Protection Agency has reviewed research undertaken to examine the suggested links between emissions from municipal waste incinerators and effects on health. While it is not possible to rule out adverse health effects from modern, well regulated municipal waste incinerators with complete certainty, any potential damage to the health of those living close-by is likely to be very small, if detectable. This view is based on detailed assessments of the effects of air pollutants on health and on the fact that modern and well managed municipal waste incinerators make only a very small contribution to local concentrations of air pollutants. The Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment has reviewed recent data and has concluded that there is no need to change its previous advice, namely that any potential risk of cancer due to residency near to municipal waste incinerators is exceedingly low and probably not measurable by the most modern techniques.
    [Show full text]
  • United Kingdom, the Netherlands and France) in Terms of Epidemiological Response and Preparedness for a Disaster Practicum Dissertation
    Environment and health Comparison of three European countries (United Kingdom, the Netherlands and France) in terms of epidemiological response and preparedness for a disaster Practicum Dissertation Marta Sala Soler, Philippe Pirard, Yvon Motreff Summary List of acronyms 2 1. Introduction 4 2. Objective 5 3. Methods 6 3.1 Choice of the material 6 3.2 Bibliographic review 6 3.3 Exchange with other institutes 6 4. Results 7 4.1 Description of the respective epidemiological responses 7 4.2 Comparison points 21 5. Discussion 26 5.1 Health Risk Assessment 27 5.2 Biomonitoring 27 5.3 Community involvement 28 5.4 Epidemiological response 29 5.5 Health Reference Values 33 5.6 Information to population and stakeholders 34 6. Conclusion 35 Bibliography 38 Comparison of three European countries in terms of epidemiological response and preparedness for a disaster — French Institute for Public Health Surveillance Comparison of three European countries (United Kingdom, the Netherlands and France) in terms of epidemiological response and preparedness for a disaster Practicum Dissertation Marta Sala Soler, Philippe Pirard, Yvon Motreff This report was written and presented by Marta Sala Soler, to obtain a second year Master's degree of Public Health (MPH) of the French School of Public Health (EHESP), Rennes. It was part of an internship that took place from February to June 2010 at the French Institute for Public Health (InVS), within the Accidents and Physical Risks Unit of the Environmental Health department. At the InVS, participants to this work
    [Show full text]
  • Dr. John Harrison
    Dr. John Harrison Dr. John Harrison is Director of the Public Health England (PHE), Centre for Radiation, Chemical and Environmental Hazards (CRCE) which has headquarters at Chilton, near Didcot in Oxfordshire. Dr. Harrison joined the National Radiological Protection Board (NRPB) in 1974 having gained a B.Sc. in Biochemistry at University College, Wales, and Ph.D. in Biochemistry at St. George's Hospital Medical School, University of London. His doctoral thesis dealt with the biological behaviour of indium and gallium radioisotopes and their use in radiopharmaceuticals. For many years, he was Head of the Radionuclide Effects Group of Radiation Effects Department within NRPB. More recently, he has been Head of Dose Assessments Department and later Deputy Director for Research in the same institute which has a broadened remit as the Centre for Radiation, Chemical and Environmental Hazards (CRCE), first within the Health Protection Agency (HPA) and now part of Public Health England (PHE). Dr. Harrison was a member of the UK Government Committee Examining Radiation Risks of Internal Emitters (CERRIE), which was set up to examine claims that radiation risks from internal emitters are being underestimated by orders of magnitude. He is coordinator of the EU FP7 SOLO project (full title: Epidemiological Studies of Exposed Southern Urals Populations). This project runs until 2015 and is concerned with establishing dose - response relationships for cancer and non-cancer disease induced by radionuclides and external radiation as a result of working at the Russian Mayak plutonium production plant or living near to the Techa River into which radioactive waste was discharged. He is also HPA representative on the Board of the Multidisciplinary European Low Dose Initiative Association (MELODI).
    [Show full text]
  • UK Health Protection Agency
    WHO International EMF Project IAC Meeting 06-07 June 2013 Report from Public Health England Public Health England is the new expert national public health agency which fulfils the English Secretary of State for Health’s statutory duty to protect health and address inequalities, and executes his power to promote the health and wellbeing of the nation. The radiation protection functions of the former Health Protection Agency (HPA) have moved to PHE and remain UK-wide in scope. PHE has operational autonomy. It has an Advisory Board with a non-executive Chairman and non-executive members. The Centre for Radiation, Chemical and Environmental Hazards is the focus of PHE’s expertise on ionising and non-ionising radiations. It undertakes research to advance knowledge about protection from the risks of these radiations; provides laboratory and technical services; runs training courses; provides expert information and has a significant advisory role in the UK. PHE has a new website (www.gov.uk/phe), which is part of a unified website that is being developed to bring together information and services from across UK Government organisations. PHE has taken responsibility for the web material previously available from HPA and has provided a link to it though “Health Protection A to Z” from the PHE homepage while a new repository for advisory material is developed. This report focuses first on recent scientific advice and related policy developments, then on research carried out at PHE and finally on the work of the independent Advisory Group on Non- ionising Radiation (AGNIR), which reports to PHE. 1 Formal advice and policy developments 1.1 Low frequency fields SAGE was a Government supported stakeholder group which has looked at the feasibility of options for reducing exposure to power frequency electric and magnetic fields as part of a precautionary policy.
    [Show full text]
  • The Health Protection Agency Bill
    RESEARCH PAPER 04/47 The Health Protection 17 JUNE 2004 Agency Bill [HL] Bill 99 2003-04 The Health Protection Agency was established on 1 April 2003, as a Special Health Authority under the NHS Act 1977. The aim of the Health Protection Agency Bill is to establish the Agency as a non- departmental public body, incorporating the National Radiological Protection Board and thereby formally bring together all the elements of health protection and emergency planning to provide a comprehensive health protection system. The Health Protection Agency Bill would provide the Agency with a wider range of functions than those presently available to a Special Health Authority. Kate Haire SCIENCE AND ENVIRONMENT SECTION HOUSE OF COMMONS LIBRARY Recent Library Research Papers include: 04/31 Individual ministerial responsibilities – issues and examples 05.04.04 04/32 Unemployment by Constituency, March 2004 16.04.04 04/33 The Human Rights Clause in the EU's External Agreements 16.04.04 04/34 Age-Related Payments Bill [Bill 92 of 2003-04] 29.04.04 04/35 Economic Indicators [includes article: Offshoring] 04.05.04 04/36 The Energy Bill [HL] [Bill 93 of 2003-04] 06.05.04 04/37 The Nuclear Decommissioning Authority: Part 2 of the Energy Bill [HL] 06.05.04 [Bill 93 of 2003-04] 04/38 Election Timetables 04.05.04 04/39 Unemployment by Constituency, April 2004 12.05.04 04/40 Parliamentary pay and allowances 18.05.04 04/41 The Patents Bill [HL] [Bill 90 of 2003-04] 03.06.04 04/42 Social Indicators [includes article: Summer Olympic Games: Facts 07.06.04 and Figures
    [Show full text]
  • Wireless Technology and Health Outcomes: Evidence and Review
    Wireless Technology and Health Outcomes: Evidence and Review Are there human health effects related to the use of wireless internet technology (Wi-Fi)? Dr. Ray Copes, Director of Environmental and Occupational Health, Ontario Agency for Health Protection and Promotion Dr. Lawrence Loh, community medicine resident, Ontario Agency for Health Protection and Promotion Background Wireless internet technology (also known by its trademark name Wi-Fi) initially was conceived in the mid 1980s but only came into widespread use in the mid-2000s, most notably as part of municipal free- internet projects1 (e.g. Toronto Hydro OneZone2.) Today, wireless internet is ubiquitous in homes, hotels, airports, and public institutions such as schools, libraries and long-term care homes. Although Wi-Fi is a relatively new communication technology, use of the radiofrequency (RF) band for communications and other applications is not new and widespread public exposure to these frequencies has occurred for decades. In addition to Wi-Fi, numerous other technologies also employ the RF band, including cellular phones and their base tower infrastructure, conventional television and radio signals, 3 home cordless phones, and microwave ovens. The RF band is a band of non-ionizing radiation that ranges from 3 kHz – 300,000 MHz1, 4, 5. The RF band is part of the electromagnetic spectrum, with frequencies below those associated with visible light and X-rays and higher than those frequencies associated with power lines. Unlike the much higher frequencies associated with X-rays and ultraviolet radiation, including sunlight, RF lacks sufficient energy to break chemical bonds. Of these technologies, the bulk of research in RF has been on cellular phones.
    [Show full text]
  • Evidence-Based Methodologies for Public Health
    TECHNICAL REPORT Evidence-based methodologies for public health www.ecdc.europa.eu ECDC TECHNICAL REPORT Evidence-based methodologies for public health How to assess the best available evidence when time is limited and there is lack of sound evidence Suggested citation: European Centre for Disease Prevention and Control. Evidence-based methodologies for public health – How to assess the best available evidence when time is limited and there is lack of sound evidence. Stockholm: ECDC; 2011. Stockholm, September 2011 ISBN 978-92-9193-311-2 doi 10.2900/58229 © European Centre for Disease Prevention and Control, 2011 Reproduction is authorised, provided the source is acknowledged. TECHNICAL REPORT Evidence-based methodologies for public health Foreword The target audience for this document are public health professionals and policymakers who work in the field of collecting, analysing and evaluating scientific evidence for the purpose of giving evidence-based public health advice for communicable diseases. By this report, we want to address the questions of giving advice under uncertainties, in complex situations and often on short notice. In the founding regulation of the European Centre for Disease Prevention and Control (ECDC), it is stated that ECDC was established to enhance the capacity of the European Community and the Member States to protect human health through the prevention and control of human diseases – to identify, assess and communicate current and emerging threats by communicable diseases. According to Article 3 in Regulation 851/2004, ECDC shall; (a) search for, collect, collate, evaluate and disseminate relevant scientific and technical data; (b) provide scientific opinions and scientific and technical assistance, including training; and (c) provide timely information to the Commission, the Member States, Community Agencies and international organisations active within the field of public health.
    [Show full text]
  • Possible Contamination of Organ Preservation Fluid with Bacillus Cereus: the United Kingdom Response
    Rapid communications Possible contamination of organ preservation fluid with Bacillus cereus: the United Kingdom response C S Brown ([email protected])1,2, M A Chand1,3, P Hoffman4, N Woodford5, D M Livermore5, S Brailsford6, S Gharbia7, N Small8, E Billingham9, M Zambon1, K Grant10, on behalf of the United Kingdom incident response team 1. Microbiology Services Division, Health Protection Agency, London, United Kingdom 2. Centre for Clinical Infection and Diagnostics Research, King’s College London, London, England 3. University College London Hospitals, London, United Kingdom 4. Laboratory of Healthcare-associated Infection, Health Protection Agency, London, United Kingdom 5. Antibiotic Resistance Monitoring & Reference Laboratory, Health Protection Agency, London, United Kingdom 6. Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, London, United Kingdom 7. Department of Bioanalysis and Horizon Technologies - Applied and Functional Genomics Unit, Health Protection Agency, London, United Kingdom 8. Imaging Acute and Community Care, Medicines and Healthcare products Regulatory Agency, London, United Kingdom 9. NHS Blood and Transplant, London, United Kingdom 10. Laboratory of Gastrointestinal Pathogens, Health Protection Agency, London, United Kingdom Citation style for this article: Brown CS, Chand MA, Hoffman P, Woodford N, Livermore DM, Brailsford S, Gharbia S, Small N, Billingham E, Zambon M, Grant K, on behalf of the United Kingdom incident response team. Possible contamination of organ preservation fluid with Bacillus cereus: the United Kingdom response. Euro Surveill. 2012;17(18):pii=20165. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20165 Article submitted on 23 April 2012/ published on 3 May 2012 We describe here the United Kingdom (UK) response Background following the recent international recall of an organ B.
    [Show full text]
  • Communicable Disease Outbreak Management: Operational Guidance About Public Health England
    Communicable Disease Outbreak Management Operational guidance Version Communicable Disease Outbreak Management: Operational guidance About Public Health England Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through advocacy, partnerships, world-class science, knowledge and intelligence, and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health. Public Health England 133-155 Waterloo Road Wellington House London SE1 8UG Tel: 020 7654 8000 http://www.gov.uk/phe Twitter: @PHE_uk This version prepared by: Helen McAuslane, Dilys Morgan, CIDSC For queries relating to this document, please contact: © Crown copyright 2014 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v2.0. To view this licence, visit OGL or email [email protected]. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. Any enquiries regarding this publication should be sent to [email protected]. You can download this publication from www.gov.uk/phe Published August 2014 PHE publications gateway number: 2014252 Page 2 of 66 Communicable Disease Outbreak Management: Operational guidance DOCUMENT INFORMATION Title Communicable Disease Outbreak Management: Operational Guidance PHE Centres, Health Protection Teams, Field Epidemiology
    [Show full text]
  • Health Protection Agency Annual Report and Accounts 2008
    HC 622 ISBN 978-0-10-295578-1 Health Protection Agency Annual Report and Accounts 2008 Erratum Page 9, fifth paragraph According to the Met Office, nearly 40cm of rain fell between May and July 2007, making it the wettest May to July period since records began in 1766. July 2008 London: The Stationery Office HEALTH PROTECTION AGENCY ANNUAL REPORT & ACCOUNTS 2008 Protecting people’s health SOME HIGHLIGHTS FROM Avian infl uenza H7N2 infection confi rmed H7N2 avian infl uenza is found in birds on a small farm in north Wales. The Agency provides expert support and advice to the National Public Health Service for Wales and carries out tests on 2007/08 specimens from nine people associated with the incident; seven from Wales and two from north west England. Plastics fire in Northamptonshire April Three thousand people from 20 fi rms are evacuated due to a blaze at Caswell Malaria is a continuing danger to UK travellers Adhesives in Corby, Northamptonshire. The Agency’s Malaria Reference Laboratory (MRL) produces its Sixty-fi ve fi refi ghters from yearly epidemiology data, which reveals there were 1,758 cases Northamptonshire and Leicestershire of malaria reported in 2006 – an almost identical number to that Fire and Rescue Services tackle the blaze seen in 2005. and the Agency sends factsheets on the chemicals involved to the fi re and rescue Working closely with the National Travel Health Network and services and advises on health effects. Centre, and the Agency’s Travel and Migrant Health section, the MRL raises awareness of malaria risk and prevention for travellers, Tuberculosis screening at Luton school and promotes the HPA Advisory Committee on Malaria Prevention’s A child at a junior school in Luton is diagnosed with tuberculosis guidelines for health professionals advising the travelling public.
    [Show full text]
  • UK Health Protection Agency
    WHO International EMF Project IAC Meeting 05-06 June 2012 Report from the UK Health Protection Agency The Health Protection Agency (HPA) provides an integrated approach to protecting UK public health through the provision of support and advice to the National Health Service, local authorities, emergency services, other Arms Length Bodies, the Department of Health and the Devolved Administrations (Wales, Scotland and Northern Ireland). The HPA has a large network of approximately 4000 staff based at four major centres and regionally and locally throughout England. The Centre for Infections at Colindale is the base for communicable disease surveillance and specialist microbiology. The National Institute for Biological Standards and Control (NIBSC) at South Mimms assures the quality of biological medicines. The Centre for Radiation, Chemical and Environmental Hazards (CRCE) has its headquarters at Chilton and the Centre for Emergency Preparedness and Response, focusing on applied microbiological research and emergency response, is based at Porton Down. There is also a small central office based in London. CRCE carries out the Health Protection Agency’s work on ionising and non-ionising radiations. It undertakes research to advance knowledge about protection from the risks of these radiations; provides laboratory and technical services; runs training courses; provides expert information and has a significant advisory role in the UK. As part of wide-ranging reforms to the health systems in the UK, the HPA is to be abolished from April 2013 and a new organisation called Public Health England (PHE) is being established. PHE will be an Executive Agency and include the functions of the HPA.
    [Show full text]